Alunbrig (brigatinib) NDC 63020-113

NDC codes

FDA NDC Directory

Product NDC (as listed)63020-113Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63020-0113Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63020-113-30	63020011330	30 TABLET, FILM COATED in 1 BOTTLE (63020-113-30)Marketed from Oct 2, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alunbrig
Generic name (nonproprietary): brigatinib
Active ingredients: Brigatinib — 30 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Takeda Pharmaceuticals America, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 208772
Marketing start: Apr 28, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 3A Inducers (Mechanism)Tyrosine Kinase Inhibitors (Mechanism)
Identifiers: Product ID 63020-113_176eb255-05c0-4cfc-874f-1fb57136d34dSPL ID 176eb255-05c0-4cfc-874f-1fb57136d34dSPL set ID 0fe9ff20-d402-41f3-bc1e-7002ea7007dbRxCUI 1921222, 1921228, 1925494, 1988768, 1988770, 1988772, 1988785, 1988786UNII HYW8DB273J
Pharmacologic class: Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463020011330 followed by a unit qualifier and the quantity

Package 63020-0113-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 12, 2026.

Indications (excerpt from the label)

ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 208772

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 208772
Product	Strength	Form · route	Labeler	Product NDC
Alunbrigbrigatinib	—	Kit	Takeda Pharmaceuticals America, Inc.	63020-198
Alunbrigbrigatinib	Brigatinib 90 mg/1	Tablet, Film coatedOral	Takeda Pharmaceuticals America, Inc.	63020-090
Alunbrigbrigatinib	Brigatinib 180 mg/1	Tablet, Film coatedOral	Takeda Pharmaceuticals America, Inc.	63020-180